ReviewCancer biology & therapy2011
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Review in Cancer biology & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Prognostic significance of serum soluble DR5 levels in small-cell lung cancer.International journal of medical sciences · 2019Trial
- TRAIL-resistant glioma cells resist Withania somnifera mediated apoptosis via USP5 upregulation.Scientific reports · 2025Article
- Advances in the Application of Apoptotic Proteins and Alternative Splicing in Tumor Therapy: A Narrative Review.Iranian journal of public health · 2023Review
- Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity.Frontiers in immunology · 2022Review
- Targeting apoptosis in cancer therapy.Nature reviews. Clinical oncology · 2020Review
- Using natural products to promote caspase-8-dependent cancer cell death.Cancer immunology, immunotherapy : CII · 2017Review
- TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA.Cell death discovery · 2017Article
- Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment.Oncotarget · 2016Article
- Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.Cell death & disease · 2016Article
- Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis.Current oral health reports · 2016Article
- hnRNPK inhibits GSK3β Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells.Scientific reports · 2016Article
- Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.Oncotarget · 2016Article
- Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- TRAIL on trial: preclinical advances in cancer therapy.Trends in molecular medicine · 2013Review
- Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.Oncotarget · 2013Article
- Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.Cell death & disease · 2013Article
- Computational modelling of LY303511 and TRAIL-induced apoptosis suggests dynamic regulation of cFLIP.Bioinformatics (Oxford, England) · 2013Article
- Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.Cancer biology & therapy · 2013Article
- Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells.Oncotarget · 2012Article
- Effect of anti-DR5 and chemotherapy on basal-like breast cancer.Breast cancer research and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Molecularly targeted therapies, such as antibodies and small molecule inhibitors have emerged as an important breakthrough in the treatment of many human cancers. One targeted therapy under development is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) due to its ability to induce apoptosis in a variety of human cancer cell lines and xenografts, while lacking toxicity in most normal cells. TRAIL and apoptosis-inducing agonistic antibodies to the TRAIL death receptors have been the subject of many preclinical and clinical studies in the past decade. However, the sensitivity of individual cancer cell lines of a particular tumor type to these agents varies from highly sensitive to resistant. Various chemotherapy agents have been shown to enhance the apoptosis-inducing capacity of TRAIL receptor-targeted therapies and induce sensitization of TRAIL-resistant cells. This review provides an overview of the mechanisms associated with chemotherapy enhancement of TRAIL receptor-targeted therapies including modulation of the apoptotic (death receptor expression, FLIP, and Bcl-2 or inhibitors of apoptosis (IAP) families) as well as cell signaling (NFκB, Akt, p53) pathways. These mechanisms will be important in establishing effective combinations to pursue clinically and in determining relevant targets for future cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.